Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.04 USD | -3.63% |
|
-7.20% | +20.83% |
04/06 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
03/06 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.83% | 1.94B | |
+12.99% | 7.03B | |
-31.51% | 6.68B | |
+8.94% | 5.25B | |
-18.46% | 4.67B | |
+14.44% | 4.07B | |
-20.81% | 3.77B | |
-29.50% | 2.66B | |
-3.09% | 1.99B | |
+2.32% | 1.83B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating